Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

Table 3

Enzalutamide advantage over abiraterone (without and with adjustment for baseline Gleason score) in months ( value).

	Unadjusted	Adjusted
OS
Predocetaxel	5.9 (<0.001)	19.5 (<0.001)
Postdocetaxel	0.8 (0.28)	1.5 (0.7)
PFS
Predocetaxel	8.3 (<0.001)	14.6 (<0.001)
Postdocetaxel	1.2 (0.02)	2.2 (<0.001)

More detailed results are available in Supplemental S4 and S5.